Cre/loxP recombination enables cellular specificity and, in the case of inducible systems, temporal control of genomic deletions. Here we used a SM22a tamoxifen-inducible Cre line to inactivate b1 integrin in adult smooth muscle. Interestingly, analysis of two distinct b1 loxP transgenic mice revealed vastly different outcomes after b1 integrin deletion. Lethality occurred 4 weeks postinduction in one Cre/loxP line, while no apparent phenotype was seen in the other line. Genetic analysis revealed appropriate DNA excision in both cases; however, differences were found in the degree of protein loss with absolutely no change in protein levels in the model that lacked a phenotype. Seeking to understand protein persistence despite appropriate recombination, we first validated the flox allele using a constitutive Cre line and demonstrated its ability to mediate effective protein inactivation. We then examined the possibility of heterozygous cell selection, protein turnover, and deletion efficiency with no success for explaining the phenotype. Finally, we documented the presence of the Cre-recombination episomal product, which persisted in tissue samples with no protein loss. The product was only noted in cells with low proliferative capacity. These findings highlight the potential for protein expression from the products of Crerecombinase excised genes, particularly when deletion occurs in low turnover populations.
I
NTEGRINS are a group of transmembrane, extracellular matrix receptors composed of heterodimeric pairs of a-and b-subunits that have been shown to function in cell survival, migration, and mechanotransduction (Schmidt et al. 1993; Wang et al. 1993; Chen et al. 1997; Hynes 2002; Stupack and Cheresh 2002; MartinezLemus et al. 2005; Abraham et al. 2008) . To study the function of b1 integrin in vivo, knockout mice were generated by homologous recombination and found to be embryonic lethal prior to implantation (Fassler and Meyer 1995; Stephens et al. 1995) . Due to this early lethality, Cre/ loxP technology has been employed to dissect the contribution of b1 integrin in specific cell types (Raghavan et al. 2000; Pietri et al. 2004; Jones et al. 2006; Lei et al. 2008) .
As with all targeted recombination technologies, the Cre/loxP system has advantages and some known limitations (Branda and Dymecki 2004) . In the case of loxP sites, location is critical. LoxP sites can flank miRNAs resulting in their inadvertent deletion (Kuhnert et al. 2008 ) and insertion of a floxed neo cassette in the intron of a gene has been shown to unintentionally disrupt gene splicing (Wassarman et al. 1997; Meyers et al. 1998) . Furthermore, unidentified alternative transcriptional start sites (Han and Zhang 2002) may circumvent attempts to inactivate a gene by loxP flanking a single exon. Given these caveats, it is important to use multiple controls to facilitate data interpretation and, whenever possible, validate the phenotype with an additional floxed allele having loxP sites located in different regions of the gene.
Four b1 integrin loxP constructs have been developed (Potocnik et al. 2000; Raghavan et al. 2000; Graus-Porta et al. 2001; Keller et al. 2001) . Each of these transgenic alleles varies in their placement of loxP sites; however, they all have been shown to successfully eliminate b1 integrin protein when used with constitutive Cre-expressing systems (Li et al. 2005; Benninger et al. 2006; Jones et al. 2006; Lei et al. 2008) . Our goal was to examine b1 integrin gene deletion in smooth muscle of adult mice. For this, we decided to use two distinct loxP transgenes designed to inactivate b1 integrin: an allele with loxP sites flanking exon 3 (b1 e3 ) (Raghavan et al. 2000) and another allele with loxP sites spanning the region between exon 2 and the 39-UTR (b1 fl ) (Potocnik et al. 2000) . Both transgenic mice were crossed to an inducible SM-22a Cre-recombinase mouse (Kuhbandner et al. 2000) to temporally restrict deletion in adult smooth muscle cells.
To our surprise, the double transgenic lines provided different phenotypes despite clear verification of genomic Supporting information is available online at http:/ /www.genetics.org/ cgi/content/full/genetics.110.121608/DC1. 1 recombination. Assessment of protein levels showed gradual protein loss in the b1 e3 -Cre mouse, but no loss of protein was seen in the b1 fl -Cre mouse. This study communicates our path to reconcile the conundrum of having genomic recombination and yet no loss of protein, and in the process we provide evidence for episomal protein expression.
MATERIALS AND METHODS

Mice: b1
fl/fl mice (Potocnik et al. 2000) were a gift from Reinhard Fassler (Max Planck Institute of Biochemistry, Germany). The b1 e3/e3 (Raghavan et al. 2000) , SM22aCre (Holtwick et al. 2002) , R26R (Soriano 1999) , and the b1 1/À (Stephens et al. 1995) mice were purchased from Jackson Laboratories (Bar Harbor, ME). The SM22aCre-ER T2 mice (Kuhbandner et al. 2000) were generously provided by Robert Feil (Interfakultäres Institut für Biochemie, Universität Tübingen, Germany). SM22a protein binds actin and contributes to smooth muscle contractility ( Je and Sohn 2007; Assinder et al. 2009 ) and is expressed specifically in adult smooth muscle cells of the vasculature and viscera. Genotyping primers used are listed in supporting information, Table S1 .
Tamoxifen (MP Biomedical) was prepared at a concentration of 20 mg/ml in 10% ethanol and 90% sunflower seed oil (Sigma) according to previous reports (Monvoisin et al. 2006) . Animals were allowed to mature (5-6 weeks old) and then received 1 mg of tamoxifen at 24-hr intervals for the specified number of injections. Mice receiving the 28-day injection regimen were aged an additional 2 weeks prior to evaluation.
Tissue to be immunostained was fixed in 2% PFA overnight. Samples were histologically sectioned and stained according to the manufacturer's protocol for phosphorylated histone 3 (Cell Signaling; 1:100). FITC-conjugated a-sm actin (Sigma, 1:100) was used for staining the bladder tissue.
b-Gal staining: To facilitate penetration of the reagents, the mucosa was dissociated from the bladder under a dissecting microscope. Embryos were stained whole mount. Tissue was then fixed at room temperature for 15 min in glutaraldhyde (0.2% glutaraldehyde, 5 mm EGTA pH 8, 2 mm MgCl, 13 PBS, pH 7.3). This was followed by three rinses of 30 min in detergent wash solution (2 mm MgCl, 0.01% DOC, 0.02% NP40, 13 PBS, pH 7.3). Tissues were stained overnight on an incubated shaker at 37°in detergent rinse with 5 mm ferrocyanide (II), 5 mm ferricyanate (III), 20 mm Tris, pH 7.3, and 1 mg/ml X-gal, pH 7.3. After staining overnight, samples were washed several times in 13 PBS at room temperature. Then they were fixed in 2% PFA overnight at 4°.
Western blot analysis: After the mucosa was removed, a portion of the bladder was placed in RIPA buffer (Lee et al. 2006) . The Western blot antibodies used were anti-b1 integrin (Millipore, 1:750), anti-a-tubulin (Sigma, 1:5000) and GAPDH (Millipore, 1:5000).
Cell culture: Mouse embryonic fibroblasts (MEFs) were isolated from E13.5-E16.5 embryos according to Nagy et al. (2003) . Mitomycin C (Calbiochem) was prepared at 200 mg/ml in HBSS and then filtered at 0.2 mm. Cells were incubated in 15 mg/ml mitomycin C in media for 3 hr at 37°. Cells were then rinsed two times with 13 HBSS and fresh media were added. Cells were allowed to recover overnight before replating. Induced quiescence was confirmed by a 6-hr incubation in 100 mm BrdU followed by fixation in 2% PFA for 30 min. Cells were then stained for BrdU incorporation using an anti-BrdU antibody (Thermo Scientific) and analyzed via confocal microscopy. Adeno-cre and adeno-gfp control viruses were applied to cells at an MOI of 30. DNA and protein were isolated from each treatment group, which included mock-infected controls.
Quantitative PCR primer design: Unique quantitative PCR (qPCR) primers were designed to facilitate a quantitative analysis of the rate of b1 loxP recombination and the rate of maintenance of the loxP-flanked DNA sequence (see Table S1 for primer sequences). The first primer set, ''total-DNA,'' was designed to quantify the total number of chromosomal copies in each DNA sample from a template. This value was used to normalize all subsequent quantitative PCR values.
To determine the rate of recombination, a pair of primers, ''unrecombined,'' was designed to anneal to the sequences on either side of a loxP site in the unrecombined b1 integrin locus. Following Cre-mediated excision of the loxP-flanked sequence, these primers anneal to distinctly separate fragments of DNA and will not generate an amplicon. Thus, the difference in the value from this primer set relative to the value from the total-DNA primer set indicates the degree to which the b1 integrin gene has been recombined and excised.
The total number of copies of b1-flanked DNA, both unrecombined (chromosomal) and recombined (episomal circles), were determined by the ''flanked DNA'' primer set. This primer set amplifies a segment just upstream of exon 3 that lies within the loxP-flanked region in both b1 fl and b1 e3 cells. Comparison of the value from this primer set relative to the value from the total-genomic primer set indicates the degree of loss of loxP-flanked sequence.
Validation experiments with these primers confirmed that each pair gave a unique, correctly sized product and that this was quantitative, relative to the amount of template present. The exception to this was the unrecombined-b1 fl primer set, which produced a marginal amount of an incorrectly sized product. To eliminate this from the analysis, a TaqMan probe was designed for this template to ensure that only the correct product was quantified.
Determination of recombination and floxed DNA persistence: DNA was extracted from bladder tissue, cardiac tissue, or MEFs using Phase Lock gel tubes (5 PRIME) according to the manufacturer's instructions. DNA was then resuspended in water and the concentration was normalized prior to PCR. Primer sequences are included in Table S1 .
For qPCR, DNA was resuspended in TE (10 mm Tris, 1 mm EDTA) and subjected to qPCR with the following conditions: Each DNA sample was assayed in triplicate reactions in opticalgrade, 96-well plates (Applied Biosystems, Foster City, CA). In the cases of total DNA, flanked DNA, and unrecombined-b1 e3 , each 25-ml reaction contained 12.5 ml of Power SYBR Green Universal Master Mix (Applied Biosystems), 5 ml of purified DNA template, and primers (900 nm each final concentration, IDTDNA). Unrecombined b1 fl was performed in 25 ml total reaction containing 12.5 ml of TaqMan Universal Master Mix (Applied Biosystems), 5 ml of purified DNA template, primers (900 nm each final concentration), and a FAM-conjugated TaqMan probe (250 nm final concentration; Operon, Huntsville, AL). All PCR runs were performed on an ABI 7500 Real Time Thermocycler using SDS software v.1.3 (Applied Biosystems). Reaction conditions were as follows: 10 min at 94°followed by 40 cycles of 10 sec at 94°and 30 sec at 64°. The starting template copy number of each reaction was determined by comparison to a standard curve, which was generated by the serial dilution of DNA from uninfected b1 fl or b1 e3 MEFs.
RESULTS
Induced b1 integrin deletion in vascular smooth muscle: Two floxed mice were used for deletion of b1 integrin in smooth muscle cells: b1 fl and b1 e3 ( Figure 1A ; Potocnik et al. 2000; Raghavan et al. 2000) . The b1 fl allele contains loxP sites flanking the entire proteincoding region followed by a lacZ gene that functions as a reporter for the b1 promoter in cells with at least one recombined allele ( Figure 1A ; Potocnik et al. 2000) . Expression of the lacZ reporter gene occurs upon excision of the floxed portion of the b1 integrin gene and subsequent splicing from exon 1 to a short segment of exon 2 placed in front of the lacZ gene. To examine the role of b1 integrin in smooth muscle in vivo, we crossed the b1 fl mouse to the SM22aCre (identified by ''c'' to indicate constitutive Cre) mouse, which constitutively expresses Cre-recombinase in smooth muscle and cardiomyocytes during development (Holtwick et al. 2002 ; Figure S2 ). We chose the SM22aCre because, in adult tissues, SM22a (transgelin) expression is restricted to smooth muscle cells (Duband et al. 1993; Kuhbandner et al. 2000) . Deletion of b1 integrin using this Cre line resulted in lethality with $50% of the progeny dying between E15.5 and P(0) ( Figure 1B ). The remaining progeny died prior to weaning. Due to their early lethality, the cb1 fl/fl mice could not be used to study b1 integrin deletion in the adult. To bypass this lethality, the b1 fl allele was crossed to the inducible SM22aCre-ER T2 (identified by ''i'' to indicate inducible Cre) transgenic mouse (Kuhbandner et al. 2000) .
To identify an appropriate induction protocol for deletion of b1 integrin in adult smooth muscle, a regimen of five injections of 1 mg tamoxifen was tested ( Figure 1C ). Bladder smooth muscle was collected and stained for b-galactosidase (b-gal) at either 24 hr or 48 hr postfinal injection. Each tamoxifen injection was additive to total recombination, as indicated by b-gal positive cells ( Figure 1C and Figure S1 ); however, a significant portion of cells remained negative for b-gal. To determine whether this poor degree of recombination was due to heterogeneous Cre-recombinase expression, the SM22aCre-ER T2 mouse was also crossed to the ROSA26R reporter (R26R) mouse (Soriano 1999) . As seen previously (Kuhbandner et al. 2000) , a sequence of five daily injections induced recombination in most bladder smooth muscle cells ( Figure  1C ), indicating that Cre was expressed and active in the large majority of these cells. To determine whether the low level of b-gal positive cells in the ib1 fl/fl mouse was associated with b1 integrin promoter activity in adult smooth muscle cells, bladders from the constitutive cb1 fl/1 and the cR26R were harvested and stained for lacZ expression ( Figure S1 ). In the constitutive mouse, most bladder smooth muscle cells were positive for b-gal, indicating that the b1 integrin promoter was indeed active in these cells. From this we concluded that the loxP sites flanking the b1 fl allele did not recombine as efficiently as the R26R construct, most likely due to the distance between loxP sites (Zheng et al. 2000; Coppoolse et al. 2005; Wang et al. 2009 ) which is $28 kb in b1 fl (Potocnik et al. 2000) vs. ,2 kb in R26R (Soriano 1999) . Therefore, to improve excision, additional tamoxifen injections were used.
Extending the induction protocol to 28 days increased the number of b-gal positive cells ( Figure 1D ). b1 integrin deletion was further tested in bladder protein lysates by Western blot analysis ( Figure 1E) . Surprisingly, a Western blot for b1 integrin revealed no detectable change in protein levels in the ib1 fl/fl when compared to oil-injected controls despite the clear abundance of b-gal positive cells. This was in sharp contrast to protein isolated from the hearts of perinatal cb1 fl/fl and cb1 fl/1 animals ( Figure 1E) .
Findings from the cb1 fl/fl mouse demonstrated that recombination of the b1 fl allele could indeed reduce b1 integrin protein levels. To determine whether the persistence of protein in the ib1 fl/fl mouse was due to a possible selection of heterozygous recombined cells (monoallelic recombination), we took advantage of the null (b1 À ) allele (Stephens et al. 1995) being preferentially selected to survive in the ib1 fllÀ bladders. Further, a Western blot showed reduced b1 integrin protein in ib1 fl/À bladders compared to the ib1 fl/1 ( Figure  2C ), but approximately equivalent reduction was observed in b1 1/À and the b1 fl/fl ( Figure 2D ). These data demonstrate that persistence of the b1 integrin protein in the ib1 fl/fl bladders was not the result of selection of heterozygous cells and further showed that loss of a single b1 allele was detectable by Western blot.
Cre-induced recombination products: The persistence of b1 integrin protein in the ib1 fl/fl bladders could suggest that the flox sites in the gene were not being recombined. This is unlikely as b-gal staining indicated recombination of the b1 integrin locus. Nonetheless, we verified genetic excision by PCR analysis using primers that flanked the 59 end in conjunction with the 39 reverse primer ( Figure 3A schematic) . For the PCR, bladders from six ib1 fl/fl mice were used to examine recombination in smooth muscle ( Figure 3A, b) . We used abdominal muscle ( Figure 3A, a) , which is skeletal muscle as a negative control for recombination. The results confirmed the recombination ( Figure 3A ) and supported findings from the lacZ assay (Figure 1, C and D) .
To reconcile the lack of protein loss after confirmed recombination, we examined the constitutive SM22aCre mice and assessed levels of b1 integrin protein in the heart and bladder (Figure 3 , B and C). While the bladder of the knockout had similar b1 integrin protein levels as controls ( Figure 3B ), the heart, with higher cell proliferation rate at time of recombination, showed a significant decrease in b1 integrin protein over controls ( Figure 3C and Figure S2 ). These results provide evidence that the b1 fl allele was appropriately targeted and excised during development, yet inactivation of the gene product was not accomplished in the adult bladder, despite clear evidence of recombination.
Recombination at loxP sites provides two outcomes: (a) elimination of chromosomal DNA flanking the loxP sites and (b) formation of an extrachromosomal circular product generated by the excised DNA (Sternberg and Hamilton 1981; Hoess et al. 1985; Metzger and Feil 1999) . Since excision in the inducible model was validated by PCR, we next sought the fate of the excised extrachromosomal DNA product. In the case of the b1 fl allele, the entire coding region, from the ATG translation initiation site in exon 2 to the stop codon and 39-UTR, is flanked by loxP sites and forms a circle following recombination, which we refer to as an episome. Thus, we considered that the persistent b1 integrin protein in recombined cells might result from the activity of this extrachromosomal DNA. Next, we asked whether the circular excision product was present in recombined cells. PCR analysis using primers from opposite ends of the loxP flanked DNA showed that the episomal DNA was indeed present in the bladders of both the six ib1 fl/fl mice exposed to tamoxifen and in the adult constitutive cb1 fl/1 bladders, but not in the four iR26R mice, which lack the allele, or in the four oil-injected ib1 fl/fl mice ( Figure 3D ). Generation and retention of episomes from different b1 integrin flox alleles: The generation of an episomal product by Cre-recombinase has been examined at length (Sternberg and Hamilton 1981; Hoess et al. 1985; Sternberg 1990; Bigger et al. 2001) . In fact, persistence of the episomal Cre-recombinase product was documented in plants (Srivastava and Ow 2003) and was also noted to be retained after viral Cre infection in mice (Dorigo et al. 2004; Gallaher et al. 2009 ). Yet, the potential expression from an intended and b1 e3/e3 mouse bladders. (C) Western blot analysis of bladder from ib1 e3/e3 and b1 e3/e3 adult mice exposed to 1 mg tamoxifen daily for 28 days.
gene deletion product has not been previously described in mammals. If the b1 fl episome was the reason for the persistence of b1 integrin protein in the recombined adult tissue, then utilization of a second loxP construct that disrupted the b1 integrin coding region should address protein persistence.
The b1 e3/e3 mouse has loxP sites that flank exon 3 and generate a frameshift and early termination mutation upon recombination (Raghavan et al. 2000) . We crossed the b1 e3 mouse to the SM22aCre-ER T2 mouse. Upon treatment with tamoxifen, the ib1 e3/e3 mice die 4 weeks after the final injection with 100% penetration (Figure 4A ), whereas tamoxifen-treated controls that included b1 e3/e3 and ib1 fl/1 as well as the ib1 fl/À mice remained viable throughout the experiment. PCR analysis confirmed genetic recombination ( Figure 4B ). Comparison of b1 integrin protein from bladders of ib1 e3/e3 and b1 e3/e3 mice showed the ib1 e3/e3 had a significant reduction in b1 integrin protein ( Figure 4C ). These results eliminated the possibility of an extended protein half-life. The findings further support the possibility that in the adult b1 fl mice, the persistence of protein was due to the excised b1 fl episome.
To evaluate episomal retention and expression in a more controlled environment, primary MEFs were isolated from b1 fl/fl animals. Cells were expanded and proliferative quiescence was induced by mitomycin C treatment in half of the b1 fl/fl MEFs. These lines were then subjected to either mock infection or infected with adeno-Cre virus or an adeno-gfp control virus. Mock-infected b1 fl/fl quiescent and proliferating MEFs were harvested following similar treatments to that of the infected cells, but lacking virus. Adeno-cre-infected cells were harvested for protein and DNA at 24, 48, and 96 hr postinfection. Adeno-gfp control cells were harvested at 96 hr postinfection. BrdU was used to evaluate proliferation vs. quiescence ( Figure  5A ). Indeed, the quiescent MEFs were negative for BrdU. Western blots from the b1 fl/fl MEFs indicate loss of protein at approximately the same rate as the b1 e3/e3 MEFs regardless of their proliferative status ( Figure 5B and Figure  S3 ). Quantitative PCR was performed to evaluate recombination and retention of the episome ( Figure 5, C and  D) . The qPCR findings demonstrated high levels of recombination in all cells exposed to adeno-cre ( Figure 5D ). Further, b1
fl/fl cells retained the episome in the quiescent state and lost it from proliferating cells. In contrast to the findings in the bladder, the data demonstrate that the b1 fl/fl -generated episome was not active in MEFs in culture ( Figure 5B ). Clearly the findings in vitro did not recapitulate either the rate of protein loss in vivo nor the expression from episomal recombined DNA, but demonstrated that the episome is retained in quiescent cells, while it is lost in proliferating cells.
To evaluate the episome and protein levels in vivo, protein and DNA was isolated from ib1 , and b1
, showed approximately equivalent total recombination in both Cre positive groups, but marked retention of episomal DNA with poor protein loss in the ib1 fl/fl group only ( Figure 6C ). In contrast, DNA analysis from cb1 fl/fl and b1 fl/fl hearts showed that the episome was eliminated in the cb1 fl/fl hearts, where protein also decreased significantly ( Figures 1E, 3C , and 6D). A central difference between the cb1 fl/fl hearts and the ib1 fl/fl bladders is its proliferation status at times of recombination that was verified by the proliferative marker phosphorylated histone 3 (pHis3, Figure S2 ).
DISCUSSION
Here we have shown that recombination of the b1 fl and the b1 e3 alleles in smooth muscle cells yield different outcomes. Our results indicate that this difference in phenotype can be attributed to the persistence of protein in the b1 fl allele. We addressed five hypotheses regarding the persistence of b1 integrin protein following recombination: (1) appropriate targeting, (2) heterozygous selection, (3) protein half-life, (4) recombination efficiency, and (5) episomal expression.
Testing the first three hypotheses was straightforward. Through PCR and DNA sequencing we confirmed that both loxP alleles were appropriately targeted within the b1 integrin gene. Further, work by us, as well as others, has demonstrated that both alleles were capable of reducing b1 integrin protein levels in vivo, in the presence of Crerecombinase when constitutive systems were used (Li et al. 2005; Benninger et al. 2006; Jones et al. 2006; Lei et al. 2008; Zovein et al. 2010) . b1 integrin had been shown to be important in cell survival (Stupack and Cheresh 2002; Manohar et al. 2004; Pinkse et al. 2004) .
We showed by analysis of b-gal-stained bladders from ib1 fl/1 and ib1 fl/À mice that heterozygous selection was unlikely. Finally, while the protein half-life of b1 integrin in cultured cells is 6-8 hr (De Strooper et al. 1991) , there is no information as to b1 integrin turnover in vivo. Nonetheless, the ib1 e3/e3 findings confirmed that an extended protein half-life was not causing protein persistence. Thus, having eliminated the first three hypotheses, we turned our attention to recombination efficiency.
It has been shown that even small changes in the distance between loxP sites can affect recombination efficiency (Zheng et al. 2000; Coppoolse et al. 2005; Wang et al. 2009 ). The distance between loxP sites in the b1 fl allele is $28 kb (Potocnik et al. 2000) , while the loxP sites for the b1 e3 allele (Raghavan et al. 2000) are ,2 kb apart. The 28-day protocol was developed to compensate for the inefficiency of the b1 fl construct and, indeed, we observed a significant increase in the number of b-gal positive cells when compared to the 5-day regimen. Surprisingly, there was no change in protein levels. Moreover, Western blot analysis of the b1 1/À and ib1 fllÀ bladder tissue when compared to b1 fl/fl showed that loss of a single allele was significant enough to reduce b1 integrin protein. This finding indicates that b1 integrin does not change promoter activity to compensate for lower total b1 integrin protein. Furthermore, it demonstrates that recombination efficiency of the b1 fl allele is lower than the b1 e3 , but this low efficiency is an unlikely explanation for the persistence of protein. At this point we began to consider the episomal hypothesis.
We found the episome generated by Cre-recombinase persisted in vivo, particularly with the b1 fl transgene. Interestingly, unlike the b1 e3 mice, the b1 fl recombination product included the ATG site at exon 2 through the final exon containing the stop codon. It is assumed that the lack of exon 1 and, therefore the promoter, would make this product transcriptionally irrelevant. However, recent analysis of the mouse and human genomes revealed that .50% of genes have alternative promoters and transcriptional start sites (Carninci et al. 2006) . Of the genes with alternative transcriptional start sites, 97% generate identical protein products (Carninci et al. 2006) . The persistence of the episome in the bladder of ib1 fl/fl mice and the apparent loss of the episome and subsequent protein depletion in the heart of cb1 fl/fl mice suggest potential expression in vivo. Consistent with this possibility Cre-recombinase-generated episomes have been shown to be competent for transcription in mammalian cells in culture, as well as in vivo (Bigger et al. 2001; Dorigo et al. 2004; Gallaher et al. 2009 ).
We attempted to recapitulate our in vivo data using MEFs in vitro. While we were able to generate quiescent b1 fl/fl MEFs, which retained the episome upon adeno-cremediated recombination, b1 integrin protein loss was equivalent between proliferating and quiescent b1 fl/fl MEFs. The discrepancy between the in vivo and in vitro experiments is difficult to interpret. It is possible that the promoter active in smooth muscle cells in vivo is not active in MEFs. Given the in vivo and in vitro qPCR data combined and the Western blots, it is difficult to resolve the difference in protein persistence by efficiency alone. We achieve nearly comparable recombination levels in the ib1 fl/fl and ib1 e3/e3 bladders in vivo, yet changes in total protein do not equate and, more importantly, the biological outcome of the deletion in each model is distinct. While we find in vitro analyses are valuable, it may be a less optimal approach when exploring questions of gene regulation in vivo.
In summary, our data illustrate the value of analyzing a phenotype using multiple loxP alleles and reinforce the importance of verifying protein loss, not just genetic recombination in Cre/loxP experiments. Further, protein depletion needs to be validated in vivo for every novel Cre/loxP combination. Finally, this work illustrates a new approach to the Cre/loxP system in vivo. Our data together with previous work (Dorigo et al. 2004; Gallaher et al. 2009) The impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6: 7-28.
FIGURE S2.-Cre activity and proliferation in heart and bladder in vivo. A) Whole mount and histological section of cR26R heart (pHis3 -red, Topro-blue). Arrows indicate heart. B) Phosphorylated histone3 (pHis3) staining of wild type E15.5 heart. pHis3-red, Topro-blue. C) Whole mount and histological section of a small portion of bladder from 28-day oil (oil) and tamoxifen (TMF) injected i 1 fl/fl mice. D) Phosphorylated histone (pHis3) staining of wild type adult mouse bladder. (pHis-red, -sm actin-green, topro-blue).
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